IFN-γ concentration, induction of IFN-γ signature genes, and tumor/immune cell responsiveness could serve as biomarkers to predict patient response to immunotherapy; it could also highlight the need for external manipulation of IFN-γ pathway in tumor tissue [118, 119]. The gene discussed is IFNG; the disease is neoplasm.